Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2016

Original Papers

  • Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, Halbsguth T, Meissner J, Greil R, Moosmann P, Shonukan O, Rueffer J, Flechtner H-H, Fuchs M, Diehl V, Engert A, and Borchmann P.Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. J Clin Oncol. 2016 Dec 20; 34(36):4329-4337.
  • Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 5; 127(18):2189-92. Epub 2016 Feb 1.
  • Eichenauer DA, Goergen H, Plütschow A, Wongso D, Behringer K, Kreissl S, Thielen I, Halbsguth T, Bröckelmann PJ, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group. Leukemia. 2016 Jun; 30(6):1425-7. Epub 2015 Nov 20.
  • Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, Halbsguth T, Hitz F, Soekler M, Shonukan O, Rueffer J, Flechtner H-H, Fuchs M, Diehl V, Engert A, Borchmann P. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016 Oct; 17(10):1453-1462. Epub 2016 Sep 6.
  • Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JMM, Schmalz O, V. Tresckow B, Engert A, Borchmann P. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group, Leuk Lymphoma. 2016 May; 57(5):1067-73. Epub 2015 Dec 23.

Reviews

  • Baues C, Semrau R, Gaipl US, Bröckelmann PJ, Rosenbrock J, Engert A, Marnitz S. Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma. Strahlenther Onkol. 2017 Feb; 193(2):95-99. Epub 2016 Oct 4.
  • Borchmann P, Engert A. Balancing the Risk-Benefit Ratio in the Treatment of Patients With Advanced-Stage Hodgkin Lymphoma. J Clin Oncol. 2016 Jun 10; 34(17):1975-7. Epub 2016 Apr 11.
  • Engert A, Raemaekers J. Treatment of early-stage Hodgkin lymphoma, Semin Hematol. 2016 Jul; 53(3):165-70. Epub 2016 May 12.
  • Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N, PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma—a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 May; 101:86-92. Epub 2016 Mar 6.
  • von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol. 2016 Jul; 53(3):180-5. Epub 2016 May 12.